Human medicines
Valsartan and Valsartan/HCT from 1A Pharma GmbH
The marketing authorization holder informed its supplied customers in a letter dated 06.07.2018 that a production-related contamination of the active…
Valsartan and Valsartan/HCT from Sandoz GmbH
In a letter dated July 6, 2018, the marketing authorization holder informed its customers that a production-related contamination of the active…
Recall of drugs containing the active ingredient valsartan from the Chinese manufacturer Zhejiang Huahai Pharmaceutical
Valsartan and Valsarcomp from Genericon Pharma GmbH
The marketing authorization holder has informed its supplied customers in a letter dated July 4, 2018, that the active ingredient valsartan may…
Valsartan and Valsartan-HCT from +pharma arzneimittel gmbh
The marketing authorization holder has informed its supplied customers in a letter dated 04.07.2018 that the active ingredient Valsartan may contain a…
Valsartan and Valsartan HCT from STADA Arzneimittel GmbH
The marketing authorization holder has informed its supplied customers in a letter dated 05.07.2018 that an impurity was detected during the review at…
Valsartan and Valsartan/HCT from Actavis Group PTC ehf
In a letter dated July 5, 2018, the marketing authorization holder informed its customers that the active ingredient manufacturer had detected the…
Valsartan and Valsartan/HCT from Teva B.V.
The marketing authorization holder has informed its customers in a letter dated December 31, 2009, that a production-related impurity has arisen at…
Valsartan, Valsax, Valsartan-HCT and CO-Valsax from G.L. Pharma GmbH
The marketing authorization holder informed its supplied customers in a letter dated December 31, 2009, that a production-related impurity occurred…
Limaxetin
The marketing authorization holder has informed its supplied customers in a letter dated 11.06.2018 that visible particles were found in part of a…
